Caffeine Consumption and Mortality in Diabetes

Caffeine Consumption and Mortality in Diabetes: an Analysis of National Health and Nutrition Examination Survey (NHANES) 1999-2010

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03367806

Enrollment

3052

Registered

2017-12-11

Start date

1999-01-31

Completion date

2011-12-31

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Previous studies suggested an inverse relationship between coffee consumption and mortality in the general population. Furthermore, an inverse association between coffee consumption and serum biomarkers of inflammation and insulin resistance has been described. Prospective studies showed that coffee consumption might be associated with reduction in the incidence of type 2 diabetes. Although caffeine consumption appears to be associated with a decreased risk of developing type 2 diabetes, the relationship between caffeine consumption and mortality in patients with diabetes remains uncertain. The current analysis aimed to assess the effects of caffeine consumption and caffeine source on all-cause, cardiovascular and cancer mortality among patients with diabetes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* NHANES participants from 1999 to 2010 above 18-year old, with diagnosis of diabetes

Exclusion criteria

* Implausible alimentary reports (defined as consumption of less than 500 kcal/day or more than 3500 kcal/day) * Missing information on caffeine consumption * Missing information on mortality

Design outcomes

Primary

Measure	Time frame	Description
All-cause mortality	From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years	All-cause mortality as assessed by NHANES linked National Death Index public-access

Secondary

Measure	Time frame	Description
Cardiovascular mortality	From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years	Cardiovascular mortality as assessed by NHANES linked National Death Index public-access
Cancer mortality	From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years	Cancer mortality as assessed by NHANES linked National Death Index public-access

Outcome results